AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31478708 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 116
Study 31302707 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual substantial decrease in eGFR (lowest 25%, < -1.63 ml min-1 [1.73 m]-2 year-1)
Number of subjects: 8879
Study 31302707 — intervention group
Group type: COMPARATOR
Intervention: Stable change in eGFR (middle 50%, -1.63 to 0.33)
Number of subjects: 8879
Study 31302707 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual substantial increase in eGFR (highest 25%, > 0.33)
Number of subjects: 8879
Study 28256257 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 187
Study 28256257 — intervention group
Group type: COMPARATOR
Intervention: 3-port laparoscopic cholecystectomy
Number of subjects: 187
Study 24388222 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram treatment
Number of subjects: 100
Study 25618971 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (n = 17)
Number of subjects: 34
Study 25618971 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (n = 17)
Number of subjects: 34
Study 22818896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91)
Number of subjects: 185
Study 22818896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of bevacizumab every 12 weeks (regimen B, n = 94)
Number of subjects: 185
Study 22818896 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen A
Number of subjects: 185
Study 22818896 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen B
Number of subjects: 185
Study 19206044 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetonide injection
Number of subjects: 114
Study 19206044 — intervention group
Group type: COMPARATOR
Intervention: Orbital floor triamcinolone acetonide injection
Number of subjects: 114
Study 17189654 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of vital signs and respiration (weekly monitoring of 12 parameters, monthly 24-hour recording)
Number of subjects: 461
Study 17189654 — intervention group
Group type: EXPERIMENTAL
Intervention: Home telemonitoring of vital signs and respiration
Number of subjects: 461
Study 17189654 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 461
Study 15712724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal independent components retrieved with an ICA algorithm (FastICA) and interpolated using fICI method
Number of subjects: 0
Study 15712724 — intervention group
Group type: COMPARATOR
Intervention: Standard technique for fetal mapping
Number of subjects: 0
Study 12040968 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ambroxol hydrochloride
Number of subjects: 714
Study 12040968 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ambroxol hydrochloride
Number of subjects: 714
Study 12040968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 9791656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory surgery with local anal block
Number of subjects: 80
Study 9791656 — intervention group
Group type: COMPARATOR
Intervention: Conventional inpatient surgery with regional anaesthesia
Number of subjects: 80
Study 9791656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Ambulatory and Inpatient)
Number of subjects: 80
Study 9098471 — intervention group
Group type: EXPERIMENTAL
Intervention: Echoguide embryo transfer (ultrasound control)
Number of subjects: 132
Study 9098471 — intervention group
Group type: COMPARATOR
Intervention: Clinical feel method (without ultrasound control)
Number of subjects: 132
Study 2533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite aerosol (0.3 to 160 mg/ml)
Number of subjects: 18
Study 2533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite aerosol (PD20 dose)
Number of subjects: 18
Study 2533410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite (second inhalation of same PD20 dose)
Number of subjects: 18
Study 2533410 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide 200 micrograms
Number of subjects: 18
Study 2533410 — intervention group
Group type: EXPERIMENTAL
Intervention: PD20 metabisulphite measurements
Number of subjects: 18
Study 2533410 — intervention group
Group type: EXPERIMENTAL
Intervention: PD20 metabisulphite
Number of subjects: 18
Study 727428 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of domperidone
Number of subjects: 96
Study 727428 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 96
Study 727428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30928396 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB)
Number of subjects: 50
Study 30928396 — intervention group
Group type: COMPARATOR
Intervention: Interscalene block alone (Control)
Number of subjects: 50
Study 28257731 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-formed retainer
Number of subjects: 45
Study 28257731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer fabricated by chemical cure
Number of subjects: 45
Study 28257731 — intervention group
Group type: EXPERIMENTAL
Intervention: Hawley retainer fabricated by heat cure
Number of subjects: 45
Study 26398632 — intervention group
Group type: EXPERIMENTAL
Intervention: Decoupling (DC)
Number of subjects: 105
Study 26398632 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 105
Study 24750327 — intervention group
Group type: EXPERIMENTAL
Intervention: P/R + V (Peg‐IFNα2a and Ribavirin + E1E2MF59 vaccine)
Number of subjects: 78
Study 24750327 — intervention group
Group type: COMPARATOR
Intervention: P/R (Peg‐IFNα2a and Ribavirin)
Number of subjects: 78
Study 24750327 — intervention group
Group type: EXPERIMENTAL
Intervention: P/R + V
Number of subjects: 78
Study 22134600 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR protocol (controlled intravaginal progesterone releasing insert, 1.38 g of progesterone)
Number of subjects: 191
Study 22134600 — intervention group
Group type: COMPARATOR
Intervention: PGF2alpha analogue cloprostenol (0.5 mg per animal i.m.)
Number of subjects: 191
Study 22134600 — intervention group
Group type: EXPERIMENTAL
Intervention: CIDR protocol
Number of subjects: 191
Study 22134600 — intervention group
Group type: COMPARATOR
Intervention: PGF2alpha protocol
Number of subjects: 191
Study 19554089 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and allopurinol treatment for 3-5 days before surgery
Number of subjects: 60
Study 19554089 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 17824352 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic treatment of depression in elderly individuals
Number of subjects: 0
Study 17824352 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 15631968 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based nutrition counselling and social support (Heartweb)
Number of subjects: 146
Study 15631968 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 146
Study 11561262 — intervention group
Group type: EXPERIMENTAL
Intervention: Short impulse (0.1 ms)
Number of subjects: 87
Study 11561262 — intervention group
Group type: COMPARATOR
Intervention: Long impulse (0.3 ms)
Number of subjects: 87
Study 11561262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 87
Study 9626221 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy and carmustine (BCNU)
Number of subjects: 701
Study 9626221 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and 1-(2-chloroethyl)-3(2,6 dioxo-l-piperidyl)-1-nitrosource a (PCNU)
Number of subjects: 701
Study 9626221 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and BCNU and interferon alfa (IFN)
Number of subjects: 701
Study 7962332 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict glycemic control in IDDM patients
Number of subjects: 28
Study 7962332 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test
Number of subjects: 28
Study 7962332 — intervention group
Group type: COMPARATOR
Intervention: Metyrapone test
Number of subjects: 28
Study 7962332 — intervention group
Group type: COMPARATOR
Intervention: L-arginine infusion
Number of subjects: 28
Study 3610511 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride pump spray
Number of subjects: 56
Study 3610511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 31418814 — intervention group
Group type: EXPERIMENTAL
Intervention: aP-containing vaccines
Number of subjects: 315
Study 31418814 — intervention group
Group type: COMPARATOR
Intervention: wP-containing vaccines (control group)
Number of subjects: 315
Study 31418814 — intervention group
Group type: EXPERIMENTAL
Intervention: wP-containing vaccines
Number of subjects: 315
Study 29879947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 14923
Study 29879947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14923
Study 27011177 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency repetitive transcranial magnetic stimulation (rTMS) applied bilaterally over the sensory motor area for six weeks
Number of subjects: 22
Study 27011177 — intervention group
Group type: COMPARATOR
Intervention: Placebo (SHAM)
Number of subjects: 22
Study 25264610 — intervention group
Group type: EXPERIMENTAL
Intervention: Play on the school field
Number of subjects: 25
Study 25264610 — intervention group
Group type: COMPARATOR
Intervention: Play on the playground
Number of subjects: 25
Study 22916805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet (two servings daily of beans, chickpeas, peas or lentils; about 150 g/d dry weight)
Number of subjects: 108
Study 22916805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-based diet (in sub-analysis of individuals with high lipid levels)
Number of subjects: 108
Study 22916805 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 108
Study 20165821 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide injections
Number of subjects: 16
Study 20165821 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation treatment (RT)
Number of subjects: 16
Study 18701691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) at 8:00 P.M. after oral hydrocortisone (24 mg)
Number of subjects: 25
Study 18701691 — intervention group
Group type: COMPARATOR
Intervention: Paired associative stimulation (PAS) at 8:00 P.M. after placebo
Number of subjects: 25
Study 18701691 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydrocortisone (24 mg)
Number of subjects: 25
Study 18701691 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 25
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist restraint behind the body whilst seated
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist restraint in front of the body whilst seated
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying prone with wrists restrained behind back
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying prone with arms free
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying supine with wrists restrained in front
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Seated position with wrists restrained behind the back
Number of subjects: 8
Study 15914307 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position with wrist restraint
Number of subjects: 8
Study 11929139 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic TCI
Number of subjects: 42
Study 11929139 — intervention group
Group type: COMPARATOR
Intervention: Conventional TCI
Number of subjects: 42
Study 10951799 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (50 ug) added to 20 ml of 0.125% bupivacaine
Number of subjects: 40
Study 10951799 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (50 mg) added to 20 ml of 0.125% bupivacaine
Number of subjects: 40
Study 7740948 — intervention group
Group type: EXPERIMENTAL
Intervention: Administration of cephalosporins 20 minutes before tourniquet inflation
Number of subjects: 62
Study 1492140 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone suppression test (DST)
Number of subjects: 105
Study 1492140 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive attributional style questionnaire (ASQ)
Number of subjects: 105
Study 1492140 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (ASQ)
Number of subjects: 105
Study 1492140 — intervention group
Group type: EXPERIMENTAL
Intervention: ASQ scores
Number of subjects: 105
Study 1492140 — intervention group
Group type: EXPERIMENTAL
Intervention: ASQ bad event attributions
Number of subjects: 105
Study 3699962 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoic acid
Number of subjects: 258
Study 3699962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 3699962 — intervention group
Group type: EXPERIMENTAL
Intervention: Active substances (including butylhydroxytoluene, butylhydroxyanisole, beta‐carotene, beta‐8‐apo‐carotenal, sodium metabisulfite)
Number of subjects: 258
Study 31549899 — intervention group
Group type: EXPERIMENTAL
Intervention: HRIG (KEDRAB) 20 IU/kg
Number of subjects: 118
Study 31549899 — intervention group
Group type: COMPARATOR
Intervention: Comparator (HyperRAB S/D®)
Number of subjects: 118
Study 31549899 — intervention group
Group type: EXPERIMENTAL
Intervention: HRIG (KEDRAB)
Number of subjects: 118
Study 28975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk (1200 mg calcium, 96 mg magnesium, 2.4 mg zinc, 15 μg vitamin D, 4 g FOS-inulin per day)
Number of subjects: 121
Study 28975432 — intervention group
Group type: COMPARATOR
Intervention: Regular milk (428 mg calcium per day)
Number of subjects: 121
Study 28975432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 121
Study 28975432 — intervention group
Group type: COMPARATOR
Intervention: Regular milk
Number of subjects: 121
Study 26374911 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG (0.25 g/kg)
Number of subjects: 31
Study 25934631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary nitrate supplementation as beetroot juice (4.8 mmol twice a day for 3 days)
Number of subjects: 35
Study 25934631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nitrate deplete beetroot juice)
Number of subjects: 35
Study 23632980 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy and appropriate medication
Number of subjects: 2707
Study 21823171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Trial (CT) - buprenorphine
Number of subjects: 114
Study 21823171 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Trial (CT) - methadone
Number of subjects: 114
Study 21823171 — intervention group
Group type: COMPARATOR
Intervention: Structured Protocol (SP) - buprenorphine
Number of subjects: 114
Study 21823171 — intervention group
Group type: COMPARATOR
Intervention: Structured Protocol (SP) - methadone
Number of subjects: 114
Study 18290977 — intervention group
Group type: EXPERIMENTAL
Intervention: Network-based rehabilitation programme (n=343)
Number of subjects: 708
Study 18290977 — intervention group
Group type: COMPARATOR
Intervention: Standard health and social services (Control group, n=365)
Number of subjects: 708
Study 16787802 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-dose activated charcoal (G1)
Number of subjects: 12
Study 16787802 — intervention group
Group type: COMPARATOR
Intervention: Simple dose of 1 g/kg activated charcoal (G2)
Number of subjects: 12
Study 14616409 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole with food
Number of subjects: 12
Study 14616409 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole in fasted state
Number of subjects: 12
Study 10741624 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg)
Number of subjects: 9
Study 10741624 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (1,500 mg)
Number of subjects: 9
Study 7756094 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback-controlled infusions of omeprazole (target pH 5, dose range 0-12 mg h-1) with an initial bolus of 80 mg
Number of subjects: 16
Study 7756094 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose infusions of omeprazole (8 mg h-1) with an initial bolus of 80 mg
Number of subjects: 16
Study 7756094 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bolus of 40 mg omeprazole followed by feedback-controlled infusions
Number of subjects: 16
Study 7756094 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial bolus of 80 mg omeprazole followed by feedback-controlled infusions
Number of subjects: 16
Study 2280336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoblitzelle Adapted Shame and Guilt Scale (ASGS)
Number of subjects: 63
Study 2280336 — intervention group
Group type: EXPERIMENTAL
Intervention: Harder Personal Feelings Questionnaire (PFQ2)
Number of subjects: 63
Study 2280336 — intervention group
Group type: EXPERIMENTAL
Intervention: New scales constructed from factor analyses and item analyses
Number of subjects: 63
Study 6155203 — intervention group
Group type: COMPARATOR
Intervention: Combination of bleomycin and adriamycin (chemotherapy)
Number of subjects: 31
Study 6155203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of bleomycin and adriamycin with radiation (3600-4000 rad)
Number of subjects: 31
Study 30877271 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion in MDD patients
Number of subjects: 77
Study 30877271 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram infusion in healthy controls
Number of subjects: 77
Study 30877271 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion in MDD patients
Number of subjects: 77
Study 30877271 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion in healthy controls
Number of subjects: 77
Study 30877271 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater rumination self-ratings in MDD group
Number of subjects: 77
Study 28540894 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 1 mg/kg/day for 3 months
Number of subjects: 88
Study 28540894 — intervention group
Group type: COMPARATOR
Intervention: Control group (training without intervention)
Number of subjects: 88
Study 25296401 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training (12 simulated slips using visual perturbation induced by tilting a VR scene while walking on the treadmill)
Number of subjects: 24
Study 25296401 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training
Number of subjects: 24
Study 25296401 — intervention group
Group type: COMPARATOR
Intervention: Control (normal walking during the training session)
Number of subjects: 24
Study 23149239 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling (PRIME), n=16
Number of subjects: 33
Study 23149239 — intervention group
Group type: COMPARATOR
Intervention: Active control (Parenting support), n=12
Number of subjects: 33
Study 23149239 — intervention group
Group type: COMPARATOR
Intervention: Matched control (standard care), n=5
Number of subjects: 33
Study 21729686 — intervention group
Group type: EXPERIMENTAL
Intervention: AEG35156 (650 mg) in combination with high-dose cytarabine and idarubicin
Number of subjects: 27
Study 21729686 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytarabine and idarubicin alone
Number of subjects: 27
Study 19192840 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% carbamide peroxide gel (bleaching group)
Number of subjects: 34
Study 19192840 — intervention group
Group type: COMPARATOR
Intervention: Control group (deionized water)
Number of subjects: 34
Study 19192840 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 and P60 (bleaching group)
Number of subjects: 34
Study 19192840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract AP (bleaching group)
Number of subjects: 34
Study 16983592 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant 8-week dose-dense doxorubicin plus docetaxel
Number of subjects: 607
Study 16983592 — intervention group
Group type: COMPARATOR
Intervention: 24-week schedule of doxorubicin plus cyclophosphamide followed by docetaxel (AC-DOC)
Number of subjects: 607
Study 12734908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (6.0 g/day)
Number of subjects: 24
Study 12734908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11061657 — intervention group
Group type: COMPARATOR
Intervention: Standard recommendation of 200 mg daily during the first 2 weeks (n = 166)
Number of subjects: 469
Study 11061657 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 50 mg every other day during the first 2 weeks (n = 93)
Number of subjects: 469
Study 11061657 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowly escalating dose starting with 100 mg daily (n = 107)
Number of subjects: 469
Study 11061657 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of prednisone and slowly escalating dose (n = 103)
Number of subjects: 469
Study 11061657 — intervention group
Group type: EXPERIMENTAL
Intervention: New approaches (including prednisone and slowly escalating dose)
Number of subjects: 469
Study 9077371 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF‐I [8 micrograms kg‐1 h‐1] by continuous subcutaneous infusion
Number of subjects: 7
Study 9077371 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (6 U. twice daily s.c.) for 5 days
Number of subjects: 7
Study 9077371 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% (S)
Number of subjects: 7
Study 7951761 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oil in milk formulas
Number of subjects: 4
Study 7951761 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of peanut oil from milk formulas
Number of subjects: 4
Study 2444166 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lindane shampoo for four minutes
Number of subjects: 53
Study 2444166 — intervention group
Group type: COMPARATOR
Intervention: 1% permethrin creme rinse for ten minutes
Number of subjects: 53
Study 29762273 — intervention group
Group type: EXPERIMENTAL
Intervention: Practices with high patient-centered cultures
Number of subjects: 606